Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-06-17
2008-06-17
Mondesi, Robert (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S002600
Reexamination Certificate
active
07388074
ABSTRACT:
Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notatably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells. Such conditions include atherosclerosis, post angioplasty restenosis, fibrosis associated with chronic inflammation or chemotherapy, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. Also disclosed are peptides of such mutant proteins, mutant-specific antibodies, nucleic acid molecules, particularly DNA, encoding the mutant protein and host cells transformed by such nucleic acids.
REFERENCES:
Audenaert et al. Conversion of Plasminogen Activator Inhibitor-1 from Inhibitor to Substrate by Point Mutation in the Reactive-site Loop. (1994) J. Biol. Chem. vol. 269, No. 30, pp. 19559-19564.
Tsiang et al., “Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in vivo”, Biochemistry 35: 16449-16457 (1996).
Andreasen, PA., et al, “Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes,”FEBS Letters(1994) 338:239-245.
Berkenpas, MB., et al, “Molecular Evolution of Plasminogen. Activator Inhibitor-i Functional Stability”,EMBO J. (1995) 14( 13):2969-2977.
Biemond, B.J., et al, “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation(1995) 91(4): 1175-1181.
Carrell, R.W., et al, “The Biostructural Pathology of the Serpins: Critical Function of Sheet Opening Mechanism,”Biol. ChemHoppel-Seyler (1996) 377:1-17.
Ehrlich. H.J., et al., “Alteration of Serpin Specificity by a Protein Cofactor,”J. Biol. Chem(1990) 265(22): 13029-13035.
Ehrlich, H.J., et al., “Functional Interaction of Plasminogen Activator Inhibitor Type 1 (PAI-1) and Heparin,”Biochemistry(1991) 30:1021-1028.
Erlich, H.J., et al, “Thrombin Neutralizes Plasminogen Activator Inhibitor I (PM-1) that is Complexed with Vitronectin in the Endothelial Cell Matrix,”J. Cell Biol. (1991) 115(6):1773-1781.
Erlich, H.J., et al, “Elucidation of Structural Requirements on Plasminogen Activator Inhibitor I for BindingtoHeparin,”J. Biol. Chem. (1992) 267(16): 11606-11611.
Keijer, J., et al., “On the Target Specificity of Plasminogen Activator Inhibitor 1: The Role of Heparin, Vitronectin, and the Reactive Site,”Blood(1991) 78(5): 1254-1261.
Keijer, J., et al., “The Interaction of Plasminogen Activator Inhibitor I with Plasminogen Activators (Tissue-Type and urokinase-Type) and Fibrin: Localization of Interaction Sites and Physiologic Relevance,”Blood(1991) 78(2):40 1-409.
Keijer, J., et al., “Vitronectin governs the Interaction between Plasminogen Activator Inhibitor I and Tissue-type Plasminogen Activator,”Biol. Chem. (1991) 266(16):10700-10707.
Kost, C., et al., “Mapping of Binding Sites for Heparin, Plasminogen Activator Inhibitor-i, and Plasminogen to Vitronectin's Heparin-binding Region Reveals a Novel Vitronectin-dependent Feedback Mechanism for the Control of Plasmin Formation,”J. Biol. Chem(1992) 267(17):12098-12105.
Lawrence, D.A. et al., “Structure-Function Studies of the Serpin Plasminogen Activator Inhibitor Type 1,”J. Biol. Chem. (1990) 265(33):20293-20301.
Lawrence, D.A. et al., “Engineering Plasminogen Activator Inhibitor 1 Mutants with Increased Functional Stability”,Biochemistry(1994)33:3643-3648.
Lawrence, D.A. et al., “Localization of Vitronectin Binding Domain in Plasminogen Activator Inhibitor-I,”Biiol. Chem. (1994) 269(21): 15223-15228.
Lawrence, D.A. et al., “Serpin Reactive Center Loop Mobility is Required for Inhibitor Function But Not for Enzyme Recognition”,J. Biol. Chem. (1994) 269(44):27657-27662.
Meijer, M. van, et al., “Determination of the Vitronectin Binding Site on Plasminogen Activator Inhibitor 1 (PM-I),”Federation of European Biochemical Societies(1994) 352:342-346.
Naski, M.C., et al., “Kinetics of Inactivation Of α-Thrombin by Plasminogen Activator Inhibitor-1,”J Biol. Chem. (1993) 268(17): 12367-12372.
Nykjaer, A., et al., “Purified α2-Macroglobulin Receptor/LDL Receptor-related Protein Binds Urokinase-Plasminogen Activator Inhibitor Type-i Complex,”J Biol. Chem. (1992) 267(21): 14543-14546.
Polliinen, J., et al., “Distinct Localizations of Urokinase-type Plasminogen Activator and its Type I Inhibitor under Cultured Human Fibroblasts and Sarcoma Cells,”J. Cell Biol. (1987)104:1085-1096.
Preissner, K.T., et al., “Structural Requirements for the Extracellular Interaction of Plasminogen Activator Inhibitor 1 with Endothelial Cell Matrix-associated Vitronectin,”J. Biol. Chem. (1990) 265(30);18490-18498.
Reilly, T.M., et al., “Recombinant Plasminogen Activator Inhibitor Type 1: A Review of Structural, Functional, and Biological Aspects”,Blood Coagulation and Fibrinolysis(1994) 5:73-81.
Sherman, P.M., et al., “Saturation Mutagenesis of the Plasminogen Activator Inhibitor-1 Reactive Center,”J. Biol. Chem.(1992) 267(11):7588-7595.
Shore, J.D., et al., “A Fluorescent Probe Study of Plasminogen Activator Inhibitor-1”,J. Biol. Chem. (1995) 270(10):5395-5398.
Shubeita, H.E., et al., “Mutational and Immunochemical Analysis of Plasminogen Activator Inhibitor-1”.J. Biol. Chem., (1990) 265(30): 18379-18385.
Vanderkuur et al., “Growth Hormone-dependent Phosphorylation of Tyrosine 333 and/or 338 of the Growth Hormone Receptor,”J. Biol. Chem. 270(37):21738-21744.
Lawrence Daniel A.
Stefansson Steingrimor P.
Desai Anand
Marshall & Gerstein & Borun LLP
Mondesi Robert
The Regents of the University of Michigan
LandOfFree
Mutant plasminogen activator-inhibitor type 1 (PAI-1) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant plasminogen activator-inhibitor type 1 (PAI-1) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant plasminogen activator-inhibitor type 1 (PAI-1) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813018